Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients
NCT ID: NCT07130136
Last Updated: 2026-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2026-05-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions this study aims to answer are:
* Is the safety and performance of the Osia System confirmed by study findings?
* What are the benefits of the Osia System compared to the Baha Connect System?
Participants will:
* Undergo speech performance testing in both quiet and noisy environments
* Provide ratings for various questionnaires
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stability of the Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery
NCT02096809
Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System
NCT02092610
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
NCT02022085
Evaluation of the Benefits of Bilateral Fitting in BAHS Users
NCT04006132
Evaluation of Cochlear Baha 5 SuperPower Sound Processor on the Baha Attract System
NCT02722330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cochlear™ Osia® System and Cochlear™ Baha® System
Participants undergoing transition from the Baha Connect System to the Osia System will complete a series of assessments and questionnaires designed to evaluate the clinical performance and user satisfaction of both systems.
Cochlear™ Osia® System
The Osia System consists of the OSI300 Implant, Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, Osia 2 Sound Processor Magnet Tool, Osia Fitting Software 2 (OFS 2), and Osia Smart App.
Cochlear™ Baha® System
The Baha Connect System consists of the BIA300 (BI300 Implant and BA300 Abutment), Baha 7 Sound Processor, and Baha Fitting Software 7 (BFS 7).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cochlear™ Osia® System
The Osia System consists of the OSI300 Implant, Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, Osia 2 Sound Processor Magnet Tool, Osia Fitting Software 2 (OFS 2), and Osia Smart App.
Cochlear™ Baha® System
The Baha Connect System consists of the BIA300 (BI300 Implant and BA300 Abutment), Baha 7 Sound Processor, and Baha Fitting Software 7 (BFS 7).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Implanted with a Cochlear Baha BI300 Implant in combination with a Cochlear Baha BA300 Abutment (Baha Connect)
* Mixed or conductive hearing loss in the ear implanted with the Baha Connect System
* Bone conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2, and 4 kHz) of ≤ 55 dB HL in the ear implanted with the Baha Connect System
* Experience of at least 6 months with the Baha Connect System
* Candidate is judged by the investigator to be dissatisfied with their current Baha Connect System due to medical issues, e.g., recurrent adverse skin reactions, and is considered likely to benefit from transitioning to an Osia System
* Candidate is a fluent speaker in the language used to assess speech perception performance
* Candidate is willing and able to provide written informed consent
* Candidate has a retrospective medical record from the time of implantation with the Baha Connect System which the investigational site is authorized to review
Exclusion Criteria
* Candidate with an acute infection (Holgers grade 4) at the implant site at the time of screening
* Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
* Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling
* Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation
* Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by the investigator or Sponsor to not impact this investigation)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TFS HealthScience
UNKNOWN
Cochlear
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PRS Specialist
Role: STUDY_DIRECTOR
Cochlear Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal National Ear, Nose and Throat and Eastman Dental Hospitals
London, , United Kingdom
Nottingham Auditory Implant Programme
Nottingham, , United Kingdom
Sheffield Teaching Hospitals
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLTD5858
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.